News coverage about Capricor Therapeutics (NASDAQ:CAPR) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Capricor Therapeutics earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 47.4785643879167 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
- Capricor Therapeutics (CAPR) Upgraded by ValuEngine to “Sell” (americanbankingnews.com)
- Global Cell Therapy Market 2018 – Bluebird Bio, Bone Therapeutics, Caladrius, Capricor Therapeutics, CellBioMed (healthcaretrends24.com)
- Capricor Therapeutics to Present at the MicroCap Conference on April 9, 2018 (finance.yahoo.com)
- Capricor Therapeutics (CAPR) Stock Rating Upgraded by Zacks Investment Research (americanbankingnews.com)
- Exosome Diagnostic and Therapeutics Market to Grow at a CAGR of 23.1% through 2027 (digitaljournal.com)
Several research analysts have recently issued reports on CAPR shares. HC Wainwright reaffirmed a “buy” rating and set a $8.60 price target (up previously from $6.50) on shares of Capricor Therapeutics in a research note on Friday, January 26th. Zacks Investment Research raised Capricor Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a research note on Tuesday, February 13th.
Capricor Therapeutics (NASDAQ:CAPR) last announced its earnings results on Wednesday, March 14th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). The company had revenue of $0.48 million for the quarter, compared to analysts’ expectations of $0.63 million. equities analysts expect that Capricor Therapeutics will post -0.42 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.tickerreport.com/banking-finance/3343985/capricor-therapeutics-capr-receiving-somewhat-positive-media-coverage-study-shows.html.
Capricor Therapeutics Company Profile
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.